FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037759747> ?p ?o ?g. }

• W3037759747 endingPage "e0234911" @default.
• W3037759747 startingPage "e0234911" @default.
• W3037759747 abstract "Drug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrogates of social value of Phase 1 trials performed in pediatric oncology: rates of approval of tested interventions, transition to further phases of testing and citation in subsequent primary research reports.We performed an analysis on a subset of eligible trials included in a previous meta-analysis. That study systematically searched EMBASE and PubMed for small sample size, non-randomized, dose escalation pediatric cancer Phase 1 studies of any malignancy, assessing chemotherapy and/or targeted therapy and looked at risk and benefit. The current analysis assessed all studies in that review published between January 1st 2004 and December 31st 2013 for predictors of social value. This time range allowed for at least five years of subsequent development activity. Sources of data included FDA and EMA medicine databases (for approval), ClinicalTrials.gov and EU Clinical Trials Register (for transition) and Google Scholar (for citation).One hundred thirty-nine trials enrolling 3814 patients met the eligibility criteria. Seven trials (5%) led to drugs being registered for pediatric use in therapy of cancer. Fifty-two (37%) transitioned to later phases of pediatric oncology trials according to ClinicalTrials.gov and/or EU Register. Over 90% of trials were cited by at least one subsequent primary research report or systematic review. Most of the citations were preclinical studies.Our analysis shows that treatments tested in pediatric Phase 1 trials in oncology have low rates of regulatory approval. However, a large proportion of Phase 1 trials inform further testing and development of tested interventions." @default.
• W3037759747 created "2020-07-02" @default.
• W3037759747 creator A5021930348 @default.
• W3037759747 creator A5041120613 @default.
• W3037759747 creator A5042282187 @default.
• W3037759747 creator A5068575667 @default.
• W3037759747 creator A5086205455 @default.
• W3037759747 creator A5087477764 @default.
• W3037759747 date "2020-06-24" @default.
• W3037759747 modified "2023-10-09" @default.
• W3037759747 title "Clinical development success rates and social value of pediatric Phase 1 trials in oncology" @default.
• W3037759747 cites W1895993106 @default.
• W3037759747 cites W1994528036 @default.
• W3037759747 cites W1997362383 @default.
• W3037759747 cites W2054696800 @default.
• W3037759747 cites W2075942204 @default.
• W3037759747 cites W2578213454 @default.
• W3037759747 cites W2763464608 @default.
• W3037759747 cites W2773697965 @default.
• W3037759747 cites W2788828598 @default.
• W3037759747 cites W2789816271 @default.
• W3037759747 cites W2901850091 @default.
• W3037759747 cites W2917748255 @default.
• W3037759747 cites W2928723028 @default.
• W3037759747 cites W2990699350 @default.
• W3037759747 cites W2997569907 @default.
• W3037759747 cites W3000155204 @default.
• W3037759747 cites W4206565140 @default.
• W3037759747 cites W4239589308 @default.
• W3037759747 doi "https://doi.org/10.1371/journal.pone.0234911" @default.
• W3037759747 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7313751" @default.
• W3037759747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32579564" @default.
• W3037759747 hasPublicationYear "2020" @default.
• W3037759747 type Work @default.
• W3037759747 sameAs 3037759747 @default.
• W3037759747 citedByCount "7" @default.
• W3037759747 countsByYear W30377597472021 @default.
• W3037759747 countsByYear W30377597472022 @default.
• W3037759747 countsByYear W30377597472023 @default.
• W3037759747 crossrefType "journal-article" @default.
• W3037759747 hasAuthorship W3037759747A5021930348 @default.
• W3037759747 hasAuthorship W3037759747A5041120613 @default.
• W3037759747 hasAuthorship W3037759747A5042282187 @default.
• W3037759747 hasAuthorship W3037759747A5068575667 @default.
• W3037759747 hasAuthorship W3037759747A5086205455 @default.
• W3037759747 hasAuthorship W3037759747A5087477764 @default.
• W3037759747 hasBestOaLocation W30377597471 @default.
• W3037759747 hasConcept C105795698 @default.
• W3037759747 hasConcept C118552586 @default.
• W3037759747 hasConcept C121608353 @default.
• W3037759747 hasConcept C126322002 @default.
• W3037759747 hasConcept C129848803 @default.
• W3037759747 hasConcept C143998085 @default.
• W3037759747 hasConcept C17744445 @default.
• W3037759747 hasConcept C199539241 @default.
• W3037759747 hasConcept C27415008 @default.
• W3037759747 hasConcept C2776598537 @default.
• W3037759747 hasConcept C2779473830 @default.
• W3037759747 hasConcept C2908647359 @default.
• W3037759747 hasConcept C2993561819 @default.
• W3037759747 hasConcept C33923547 @default.
• W3037759747 hasConcept C512399662 @default.
• W3037759747 hasConcept C535046627 @default.
• W3037759747 hasConcept C71924100 @default.
• W3037759747 hasConcept C95190672 @default.
• W3037759747 hasConcept C99454951 @default.
• W3037759747 hasConceptScore W3037759747C105795698 @default.
• W3037759747 hasConceptScore W3037759747C118552586 @default.
• W3037759747 hasConceptScore W3037759747C121608353 @default.
• W3037759747 hasConceptScore W3037759747C126322002 @default.
• W3037759747 hasConceptScore W3037759747C129848803 @default.
• W3037759747 hasConceptScore W3037759747C143998085 @default.
• W3037759747 hasConceptScore W3037759747C17744445 @default.
• W3037759747 hasConceptScore W3037759747C199539241 @default.
• W3037759747 hasConceptScore W3037759747C27415008 @default.
• W3037759747 hasConceptScore W3037759747C2776598537 @default.
• W3037759747 hasConceptScore W3037759747C2779473830 @default.
• W3037759747 hasConceptScore W3037759747C2908647359 @default.
• W3037759747 hasConceptScore W3037759747C2993561819 @default.
• W3037759747 hasConceptScore W3037759747C33923547 @default.
• W3037759747 hasConceptScore W3037759747C512399662 @default.
• W3037759747 hasConceptScore W3037759747C535046627 @default.
• W3037759747 hasConceptScore W3037759747C71924100 @default.
• W3037759747 hasConceptScore W3037759747C95190672 @default.
• W3037759747 hasConceptScore W3037759747C99454951 @default.
• W3037759747 hasFunder F4320322511 @default.
• W3037759747 hasIssue "6" @default.
• W3037759747 hasLocation W30377597471 @default.
• W3037759747 hasLocation W30377597472 @default.
• W3037759747 hasLocation W30377597473 @default.
• W3037759747 hasLocation W30377597474 @default.
• W3037759747 hasLocation W30377597475 @default.
• W3037759747 hasOpenAccess W3037759747 @default.
• W3037759747 hasPrimaryLocation W30377597471 @default.
• W3037759747 hasRelatedWork W2417314287 @default.
• W3037759747 hasRelatedWork W2496077116 @default.
• W3037759747 hasRelatedWork W2611523470 @default.
• W3037759747 hasRelatedWork W3082212156 @default.

• next